Clinical Trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07142707) titled 'A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity' on Aug. 04.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.

Study Start Date: Aug. 26

Study Type: INTERVENTIONAL

Condition: Obesity

Intervention: DRUG: MBX 4291

MBX 4291 will be administered subcutaneously (SC)

DRUG: Placebo

Placebo: Placebo will be administered subcutaneously (SC)

Recruitment Status: RECRUITING

Sponsor: MBX Biosciences

Disclaimer: Curated by HT Syndication...